Analysis of 1110 Cases of Drug-induced Liver Injury in 79 Hospitals

Abstract

Abstract: Objective To investigate the condition and characteristics of drug-induced liver injury(DILI), and provide reliable basis for theprevention and treatment of DILI. Methods The cases of DLLI were collected from database of PLA ADR Monitoring Center from 2008 to 2016 and then patients' information, suspicious drugs, laboratory indexes and major manifestations, occurring time of DILI and administration route, treatment and outcomes were analyzed retrospectively. Results Among 1 110 DILI cases, the ratio of males and females was 1.51:1. Significant differences of age existed between males and females (χ²=25.136, P=0.01). The three predominant drug classifications were anti-infective agents, nervous system drugs, cardiovascular system drugs orderly. The predominant drugs were atorvastatin, rifampicin, moxifloxacin and levofloxacin orderly. Significant difference of outcomes existed between patients taking liver-protecting drugs and patients not taking liver-protecting drugs (χ²=25.136,P＜0.001).Conclusion Clinical medical staffs should learn more about drugs and use them reasonably, drug withdrawal and other symptomatic treatments should be given in time for patients with DILI.

Key words: drug-induced liver injury(DILI), adverse drug reaction(ADR), appropriate medication

CLC Number:

R994.11

JIA Wang-ping, GUO Dai-hong, TIAN Xiao-yan, KOU Wei, WANG Xiao-yu, ZHAO Su-yu, HU Peng-zhou. Analysis of 1110 Cases of Drug-induced Liver Injury in 79 Hospitals[J]. Chinese Journal of Pharmacovigilance, 2017, 14(8): 481-485.

References

[1] Stirnimann G, Kessebohm K, Lauterburg B. Liver injury caused by drugs: an update[J].Swiss Med Wkly，2010, 140(w13080):1-9.
[2] Bunchorntavakul C, Reddy K R. Review article: herbal and dietary supplement hepatotoxicity[J]. Aliment PharmacolTher, 2013, 37(1):3-17.
[3] Ostapowicz G, Fontana R J, Schi?dt F V, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States[J]. Ann Intern Med，2002,137(12):947-954.
[4] 国家药品不良反应监测中心.药品不良反应术语使用指南[S].监测与评价综[2016]77号.
[5] 朱磊, 黄萍, 李颖. 162例药物性肝损害不良反应/事件报告分析[J]. 中国药物警戒, 2013, 10(7): 415-418.
[6] Amacher D E.Female gender as a susceptibility factor for drug-induced liver injury[J]. Hum Exp Toxicol, 2013, 33(9):928-939.
[7] Zhou Y,Yang L, Liao Z L, et al. Epidemiology of drug-induced liver injury in china: a systematic analysis of the Chinese literure including 21789 patients[J]. European Journal of Gastroenterology and Hepatology, 2013, 25(7): 825-829.
[8] 朱曼,郭代红,史录文，等.抗感染药致药源性肝损伤572例分析[J]. 中国药房，2015, 26(26): 3663-3666.
[9] Paterson J M, Mamdani M M, Manno M, et al. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study[J]. CMAJ, 2012,184:1565-1570.
[10] 张俊忠, 管文娟. 阿托伐他汀钙致药物性肝损害1例[J]. 中国执业药师, 2012, 9(10):42-43.
[11] 曲彩红, 宋美华, 吴瑛, 等. 阿托伐他汀与辛伐他汀联用致药物性肝损害及磷酸肌酸激酶升高[J]. 中国处方药, 2012, 10(03): 24-26.
[12] Chalasani N P,Hayashi P H,Bonkovsky H L, et al. ACG Clinical Guideline：the diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2014, 109(7): 950-966.
[13] 叶冬梅, 兰顺, 蒙石英. 262例药源性肝损害病例的药物治疗分析[J]. 中国医院用药评价与分析, 2010, 10(8):754-757.
[14] 王继美, 张翠芳, 赵守美. 94例药物性肝损害不良反应分析[J]. 中国药物警戒, 2013, 10(6):369-372.
[15] 朱磊,黄萍,李颖. 162例药物性肝损害不良反应/事件报告分析[J]. 中国药物警戒,2013,10(7):415-418.
[16] 陈有法, 王红艳. 药源性肝损害189例分析[J]. 中国药业,2010,19(15):43-44.